Safety of Ultrasound Contrast Agents in Pediatric Patients With Sickle Cell Disease and Trait

Abstract

Ultrasound contrast agent (UCA) use is increasing. Recent isolated reports observed a rise in pain‐related adverse events with the intravenous administration of the UCA Definity in adults with sickle cell disease. To date, no studies have investigated the incidence of similar adverse events with UCA Lumason or Optison. We describe our experience regarding the safety of Lumason and Optison in children with sickle cell disease and trait who underwent contrast‐enhanced ultrasound exams in our department with intravenous, intravesical, and other intracavitary routes. No pain‐related or other adverse events were observed in this pediatric population with any route of UCA administration.